NCT04536324

Brief Summary

The purpose of the study is to examine the rate of absorption of subcutaneous infused fluid in older adults when acutely ill compared to when they are not acutely ill.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 28, 2020

Completed
4 days until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 2, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2020

Completed
Last Updated

February 4, 2021

Status Verified

February 1, 2021

Enrollment Period

3 months

First QC Date

August 28, 2020

Last Update Submit

February 2, 2021

Conditions

Keywords

DehydrationFluid therapyHypodermoclysisGeriatricSodium Pertechnetate Tc 99m

Outcome Measures

Primary Outcomes (1)

  • The difference in the absorption rate between acutely ill and not acutely ill.

    We will compare the absorptions rate of subcutaneous infused fluid when the patients are acutely ill (during admission) and when they are not acutely ill (8 weeks after discharge).

    8 weeks after discharge

Secondary Outcomes (3)

  • The absorption rate of subcutaneous infused fluid by count over the infusion site

    We will count the activity from the start of infusions until 2 hours after all of the 250 ml have been infused.

  • The absorption rate of subcutaneous infused fluid by count in the thyroid or by count in blood samples.

    We will count the activity from the start of infusions until 2 hours after all of the 250 ml have been infused.

  • The correlation between s-albumin and absorption time.

    We will count the activity from the start of infusions until 2 hours after all of the 250 ml have been infused.

Interventions

Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.

Also known as: Hypodermoclysis

Eligibility Criteria

Age75 Years - 120 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admitted to the local geriatric ward will be screened for eligibility.

You may qualify if:

  • Ability to give informed consent
  • Hospitalized for an acute illness

You may not qualify if:

  • Severe limitation on fluids
  • Risk of acute deterioration of illness
  • Requiring constant care
  • Short life expectancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg University Hospital

Aalborg, Denmark

Location

Related Publications (1)

  • Danielsen MB, Jodal L, Riis J, Karmisholt JS, Valdorsson O, Jorgensen MG, Andersen S. Absorption rate of subcutaneously infused fluid in ill multimorbid older patients. PLoS One. 2022 Oct 10;17(10):e0275783. doi: 10.1371/journal.pone.0275783. eCollection 2022.

MeSH Terms

Conditions

Dehydration

Interventions

Hypodermoclysis

Condition Hierarchy (Ancestors)

Water-Electrolyte ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Infusions, SubcutaneousInfusions, ParenteralDrug Administration RoutesDrug TherapyTherapeuticsFluid Therapy

Study Officials

  • Mathias B Danielsen, MD

    Aalborg University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

August 28, 2020

First Posted

September 2, 2020

Study Start

September 1, 2020

Primary Completion

November 20, 2020

Study Completion

November 20, 2020

Last Updated

February 4, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification. Data sets will only be shared when the anonymity of included participants can be insured.

Shared Documents
STUDY PROTOCOL, ANALYTIC CODE
Time Frame
Beginning 6 months and ending 5 years following article publication.
Access Criteria
The dataset will be shared upon reasonable request.

Locations